NEW YORK (GenomeWeb) – Diagnostics manufacturer Quidel reported after the close of the market on Wednesday that its fourth quarter revenues rose 118 percent year over year, due primarily to cardiac immunoassay revenues from the newly acquired Triage and BNP businesses, as well as increased sales of rapid immunoassay products.

The firm also reported 45 percent revenue growth in its molecular diagnostics business in the quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.